This study is looking at using different experimental treatment methods for children diagnosed with Acute Myeloid Leukemia (AML) and Down Syndrome (DS) based on how well they respond to their first treatment.
7 Studies found
Study Of An Investigational Drug For Relapsed Or Refractory Cd22+ B-Acute Lymphoblastic Leukemia (B All)
Seeking children and young adults whose CD22+ B-Acute Lymphoblastic Leukemia (B ALL) has come back (relapsed) after treatment or has not responded (refractory) for a study of an investigational drug. While the investigational drug has been approved for use adults with leukemia, it has not yet been approved for use in children.
Study Of Chemotherapy For Children And Young Adults With High-Risk B-Cell Acute Lymphoblastic Leukemia (B-All)
Children and young adults up to age 25 with High-Risk B-cell acute lymphoblastic leukemia (B-ALL) sought for a study of an investigational drug in combination of chemotherapy based on individual disease characteristics to improve 5-year disease-free survival (DFS).
Seeking children and young adults 31 years old or younger who have been newly diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B ALL or localized B-cell Lymphoblastic Lymphoma (B-LLy) for a study of chemotherapy.
Seeking people aged 2-21 years who have been diagnosed with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive Acute Lymphoblastic Leukemia (ALL) for a study of whether using a less toxic chemotherapy in combination with a drug called imatinib can keep the cancer from returning after treatment.
Study Of The Addition Of An Investigational Drug To Treatment Following Stem Cell Transplant For Multiple Myeloma
Seeking men and women who have had stem cell transplant for their multiple myeloma for a study of an investigational drug to be added to the usual maintenance treatment.
Seeking men and women 18 years of age and older who have chronic myeloid leukemia (CML) in chronic phase (CP) with and without the T315I mutation, to determine how well the treatment with asciminib works compared to previously used therapies.